email article
Patients with early-stage non-small cell lung cancer (NSCLC) lived significantly longer without disease recurrence if they received atezolizumab (Tecentriq) after surgery and chemotherapy, a large randomized trial showed.
Median disease-free survival (DFS) had yet to be reached after a median follow-up of 32.8 months, but the results met criteria for statistical significance, showing a 34% reduction in the hazard ratio for patients with stage II-IIIa disease and PD-L1 tumor cell expression ≥1%, said Heather Wakelee, MD, of Stanford University Medical Center in California, during a press briefing in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting.
An analysis limited to patients with stage II-IIIa disease (irrespective of PD-L1 expression) showed they were significantly more likely to be alive and disease free if they received atezolizumab instead of best supportive care (BSC) after chemotherapy. An intention-to-treat (ITT) a
Roche aims Tecentriq at early lung cancer after data shows benefit
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Immunotherapy Takes First Major Step Into Earlier NSCLC
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Researchers examine the connection between lung cancer and COVID-19
On February 27, 2020, the flagship journal of the International Association for the Study of Lung Cancer, the
Journal of Thoracic Oncology, published a case study that described two patients from Wuhan, China who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery.
Eleven months later, the lung cancer research community gathered virtually at the IASLC 2020 World Conference on Lung Cancer Singapore to share a number of research findings examining the intersection of COVID-19 and lung cancer. Researchers from a variety of countries participated in a press briefing to examine the connection between lung cancer and COVID-19.